Category: biotech

.Invite to this week’s Chutes &amp Ladders, our roundup of significant leadership hirings, shootings and retirings all over the market. Feel free to send the

.Bristol Myers Squibb is axing one more big wager from the Caforio age, ending an offer for Agenus’ TIGIT bispecific antibody 3 years after paying

.Bristol Myers Squibb is actually paying Excellent Medicine $110 thousand upfront to develop reagents for ex-spouse vivo T-cell treatments. Excellent, which could obtain an immense

.Bristol Myers Squibb has actually had a whiplash change of mind on its BCMA bispecific T-cell engager, halting (PDF) more growth months after filing to

.AvenCell Therapies has actually safeguarded $112 million in collection B funds as the Novo Holdings-backed biotech seeks scientific verification that it can easily create CAR-T

.Atea Pharmaceuticals’ antiviral has actually stopped working an additional COVID-19 trial, but the biotech still stores out wish the applicant has a future in hepatitis

.Pinetree Therapies will definitely assist AstraZeneca vegetation some plants in its pipeline with a brand new pact to build a preclinical EGFR degrader worth $forty

.AstraZeneca has paid off CSPC Drug Team $100 thousand for a preclinical heart attack medicine. The bargain, which covers a potential competitor to an Eli

.AstraZeneca has actually discussed an early consider the efficiency of its own in-house antibody-drug conjugate (ADC) technology, publishing stage 1 record on applicants that might

.AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has stopped working to improve general survival (OS) in non-small tissue bronchi cancer (NSCLC), prolonging the listing